Optimization of XXXX dose shortens procedural sedation time, prevents resedation and removes the requirement for post-procedure physiologic monitoring.

@entity1 @entity2613 @entity1875
OBJECTIVE: To examine the effect of @entity1875 dosing (total dose and number of doses) on @entity1 sedation time and likelihood of resedation. METHODS: This was a prospective, observational @entity1 series in an urban district hospital @entity2613 with 42 000 attendances per annum. @entity1 undergoing an emergent procedure requiring procedural sedation were included. Titrated intravenous @entity1875 was administered according to departmental procedure. Standardized consent and data collection forms were used. Time taken for the @entity1 to become conversational after first administration was recorded and any resedation documented. RESULTS: Four hundred @entity1 , undergoing 404 procedures, were enrolled for the period commencing August 2004 until March 2006. The mean initial @entity1875 bolus was 0.8 mg/kg (SD 0.6), and mean total @entity1875 dose was 1.8 mg/kg (SD 1.0), comprising a mean of 2.3 (SD 2.1) doses of 15.8 mg (SD 11.4). Mean sedation time was 11.8 min (SD 6.9), and increased sedation times were associated with higher total @entity1875 dose and number of boluses (P < 0.0001). Resedation occurred in two @entity1 (0.5%, 95% CI 0-1.6%). CONCLUSION: Shorter sedation times are seen with lower doses of @entity1875 . @entity1 do not need prolonged post-procedure monitoring because the occurrence of spontaneous resedation associated with @entity1875 use is a rare event. This has implications for @entity1 flow and staff resource allocation in a busy @entity2613 .
